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Transient treatment with small molecule CDK inhibitors is toxic 
to cancer cells and leads to depletion of anti-apoptotic proteins and 
Chk1, coupled with DNA damage and induction of apoptosis. 
Here we have examined, which of these phenomena are necessary 
for CDK inhibitors to have an anti-proliferative effect. We find 
that 24 hours treatment with either a primarily CDK2-specific, or 
a primarily CDK7/9-specific, antagonist eliminates proliferative 
potential even if apoptosis is blocked and the tendency of CDK 
inhibition to result in DNA damage is overcome by expression of 
recombinant Chk1. Loss of proliferative potential is correlated with 
irreversible suppression of biomarkers of cell cycle progression. 
CDK inhibitors dramatically reduced levels of the anti-apoptotic 
proteins, Mcl-1 and XIAP, but siRNA-mediated suppression of 
Mcl-1 and XIAP did not induce cell death in the osteosarcoma 
cells used in this study. Finally, we found that many literature 
CDK inhibitors do not effectively suppress the CDK/cyclin 
complexes responsible for cell cycle progression at the minimum 
doses required to block proliferation: some are only effective after a 
substantial delay and may act via inhibition of CDK7.
Introduction
Cyclin-dependent kinases (CDKs) play cardinal roles in prolifera-
tion. CDK activation is required for commitment to another round 
of division, for the transition from G1 to S phase and for entry into 
mitosis.1 These three functions were once attributed to CDK4 or 
6, CDK2 or 3, and CDK1, respectively, but recent results indicate 
that CDK1 can perform all the essential functions of the five cell 
cycle CDKs.2 The identity of the regulatory cyclin subunit, and the 
details of how it controls the subcellular localization and activation 
dynamics of its CDK partners, may be more important for defining 
the function of CDK/cyclin complexes.3 All the above CDK/
cyclin complexes require an activating phosphorylation to become 
active, which is performed by another CDK, CDK7/cyclin H.4 As 
a member of the TFIIH complex, CDK7 also plays a role in RNA 
polymerase II transcription regulating initiation by phosphorylating 
the carboxy-terminal repeat domain (CTD) of RNA polymerase. A 
number of other CDKs also play roles in transcription, including the 
P-TEFb component, CDK9.5
CDK activity is often deregulated in transformed cells, e.g., by 
loss of stoichiometric inhibitor proteins such as p16 and p27.6 This 
cancer-specific deregulation led to the CDKs being a major target of 
the efforts to identify therapeutically useful protein kinase inhibitors 
stimulated by the success of imatinib mesylate (Gleevec) in treating 
chronic myelogenous leukemia.7 Numerous small molecule inhibitors 
of CDKs have now been identified that block cell cycle progression 
and induce apoptosis in cancer cells.8 The selectivity of known 
inhibitors is variable, but few are specific for either cell cycle or tran-
scriptional CDKs. However, as some CDK inhibitors are effective at 
treating xenografted human tumors implanted into immunocom-
promised mice,9 biased killing of cancer cells appears possible with 
certain selectivity profiles. The mechanism by which CDK inhibitors 
kill cancer cells has been controversial. An early proposal was that 
CDK2 activity is required to suppress E2F-1 driven pro-apoptotic 
transcription triggered by oncogenic signaling,10 but the dispens-
ability of CDK2 for the growth of many cancer cell lines11 has led 
to other rationales being considered. Recently, attention has been 
focused on the ability of CDK inhibitors to suppress expression of 
the short half-life anti-apoptotic proteins XIAP (a caspase inhibitor) 
and Mcl-1 (a Bcl-2 family member) via inhibition of CDK7 and/or 
CDK9. As proposed by Koumenis and Giacca in 1997,12 transformed 
cells may be particularly sensitive to interruptions in the synthesis of 
rapidly turned-over anti-apoptotic proteins. CDK7 and CDK9 are 
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frequently targeted by nominal cell cycle CDK inhibitors13 and 
the cytotoxicity of the best-characterized examples, roscovitine and 
flavopiridol, has been attributed to consequent Mcl-1 and XIAP 
depletion.14-16 Loss of CDK2 activity, however, also evokes a patho-
logical checkpoint response associated with DNA damage, impaired 
DNA repair and loss of expression of the Chk1 kinase, which likely 
also contributes to the toxicity of CDK inhibitors.17-19 Cells with 
defective BRCA1 function may be particularly susceptible to death 
via this mechanism.19
The lack of clarity around the mode-of-action of CDK inhibitors 
makes it unclear which CDK/cyclin complexes should be inhibited 
to maximize chances of success in cancer therapy. To aid our efforts 
in this area, we set out to establish how small molecule CDK inhibi-
tors kill U2-OS osteosarcoma cells, a cell line frequently used to 
study the roles of CDK/cyclin complexes.18-22 We were particularly 
interested in the consequences of blockading CDK2 and CDK1, 
the CDKs responsible for triggering S-phase and driving mitosis. 
When literature inhibitors were examined to select reagents suitable 
for use in this study, none of the commercially available compounds 
tested possessed both of the properties we considered essential: good 
potency on cells and confidence that the anti-proliferative effects 
of the compounds are mediated by inhibition of cell cycle CDK/
cyclin complexes. Consequently, we used VER-54505, a pyrazolopy-
rimidine synthesized as part of a medicinal chemistry effort to find 
CDK inhibitors suitable for cancer therapy.23 VER-54505 induced 
caspase-dependent apoptosis and a DNA damage response linked 
to Chk1 depletion, but interestingly, neither of these effects was 
required for transient treatment with VER-54505 to permanently 
block proliferation.
Results
Biomarkers of cell cycle progression do not recover after 24 
hours exposure to apoptosis-evoking doses of the CDK2 inhibitor, 
VER-54505. Given their essential role in cell division, continuous 
exposure to CDK inhibitors will suppress the growth of both trans-
formed and normal cells. Consequently, some form of transient 
treatment will be necessary if CDK inhibitors are to be used for 
anti-cancer therapy. It is therefore important to know how long 
a blockade has to be imposed for tumor cell viability to be lost. 
VER-54505, a novel CDK2 inhibitor primarily active vs. CDK2, 
was selected for this study because of its ability to rapidly suppress 
biomarkers of cell cycle related CDK/cyclin complex activity at low 
multiples of its GI50, the dose required to reduce final biomass by 
50% in a growth/proliferation assay (Figs. S1 and S2). VER-54505 
blocks entry into mitosis at lower doses than it suppresses DNA 
replication and is capable of forcing exit from mitosis (Fig. S3). 
U2-OS cells plated at low density, were treated for 2 to 24 hours with 
VER-54505, then cultured without drug for 7 days to allow colony 
formation. High doses of the compound were tolerated if applied for 
≤7 hours, but 24 hours treatment with 2x GI50 VER-54505 reduced 
colony formation by <95% (Fig. 1A). Though little apoptosis was 
evoked by 24 hours treatment with this dose, a large increase in the 
fraction of cells with sub-G1 DNA content was seen after 48 and 72 
hours treatment (Fig. 1B). Significant PARP cleavage was observed in 
populations containing 20% or more sub-G1 cells (data not shown, 
but also see Fig. 1C). Removal of drug after 24 hours did not rescue 
U2-OS cells from subsequent apoptosis.
Given that 7 hours treatment with high doses of VER-54505 
was well tolerated, we suspected that CDK inhibitors might impose 
substantial changes in cellular signaling without ill effect as long 
as the changes were reversed upon drug removal. Loss of viability 
should therefore be correlated with the subset of pharmacodynamic 
marker changes imposed by VER-54505, which were not reversed 
when the CDK inhibitor was washed out. Cells were thus treated for 
24 hours with 0.5x to 4x GI50 of VER-54505 and then lysed either 
immediately, or after 6 or 24 hours recovery without drug.
Low doses (0.5–1x GI50) of VER-54505 suppressed phospho-
rylation of the retinoblastoma protein (Rb) on Ser249/Thr252 
and histone H3 on Ser10, and also reduced expression of Chk1 
(Fig. 1C). The loss of Rb and histone H3 phosphorylation suggests 
suppression of CDK2 and CDK1 activity in cells; Rb Ser249/
Thr252 is a direct substrate for CDK2,24-26 and histone H3 Ser10 
is phosphorylated by Aurora B only during mitosis,27 for which 
CDK1 activity is essential. Inhibition of Rb and Histone H3 
phosphorylation was (at least in part) reversible, but the reduction 
imposed on Chk1 levels was longer-lasting. The higher doses (2–4x 
GI50) of VER-54505 that were associated with loss of clonogenicity 
appeared to affect additional CDK complexes. VER-54505 at ≥2x 
GI50 reduced phosphorylation of RNA polymerase II on Ser2 of 
the C-terminal heptapeptide repeat domain (an epitope phospho-
rylated by CDK9),28 and suppressed XIAP and Mcl-1 expression. 
These doses also evoked phosphorylation of Histone H2AX on 
Ser139 (a marker of DNA damage)29 and stimulated p53 expres-
sion. Though apoptotic markers were not apparent after 24 hours 
treatment with VER-54505, cleavage of caspase 7 and PARP was 
observed 6 and 24 hours after removal of ≥2x GI50 VER-54505 
(Fig. 1C). The minimum dose of VER-54505 required to eliminate 
long term proliferative potential thus corresponds to the minimum 
dose required to induce apoptosis. It was striking, however, that after 
24 hours treatment with ≥2x GI50 VER-54505, Rb Ser249/Thr252 
and histone H3 phosphorylation did not recover at all when drug 
is removed. The irreversible suppression of cyclin B1, cyclin E1 and 
Cdc25A observed at these doses may account for the lack of recovery 
of Rb and Histone H3 phosphorylation.
Is induction of apoptosis essential for the ability of transient 
treatment with CDK inhibitors to block further proliferation of 
U2-OS cells? The results above suggest that CDK inhibitors in 
part ablate long term proliferative potential by forcing cells into 
permanent cell cycle arrest. VER-54505, however, also induced 
programmed cell death, and we were keen to establish how impor-
tant a role apoptosis played in the loss of clonogenicity. U2-OS cells 
were exposed to a range of doses of VER-54505 in the presence of 
absence of 20 μM zVAD-fmk, a cell-permeable irreversible inhibitor 
of multiple caspases.30 VER-54505 was withdrawn after 24 hours, 
but exposure to the caspase inhibitors, if present, was maintained. 
zVAD-fmk substantially blocks the cleavage of caspase 3 and 7 to 
the active forms that is otherwise induced by VER-54505 (Fig. 
2A) and also prevents the appearance of cells with a sub-G1 DNA 
content (Fig. 2B). Consistent with the results shown in Figure 1B, 
24 hours treatment with VER-54505 does not immediately reduce 
cell biomass below that observed prior to treatment (Fig. 2C), but 
significant reductions are seen after a further 24 or 48 hours incu-
bation (here without drug). Addition of zVAD-fmk substantially 
rescues cells from this CDK-inhibitor induced lethality confirming 
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Figure 1. For figure legend, see page 3901.
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capacity of VER-54505 to deplete Mcl-1 and/or XIAP therefore does 
not account for its ability to induce apoptosis in U2-OS cells.
The loss of clonogenicity induced by treatment with the CDK7 
inhibitor, BMS-387032, also correlates with its ability to impose 
a permanent cell cycle arrest. One of the CDK inhibitors that has 
entered clinical trials is BMS-387032,9 also now known as SNS-032. 
BMS-387032 blocks DNA replication and entry into mitosis with 
approximately equal effectiveness, but fails to force exit from mitosis 
(Fig. S3). During our efforts to identify a CDK2 inhibitor suitable 
for this work, we found that BMS-387032 is approximately equally 
effective at inhibiting CDK2, 7 and 9 in in vitro kinase assays (Fig. 
S1). The surprisingly high potency of BMS-387032 vs. CDK7 and 
CDK9 has also been noted by Choong et al.31 BMS-387032 is a 
highly effective suppressor of biomarkers of cell cycle related CDK 
activity in 24 hour treatments, but is relatively ineffective in shorter 
exposures, despite its greater ability to traverse cell membranes 
compared to VER-54505 (Fig. S2). Time course experiments revealed 
that phosphorylation of Ser5 residues within the RNA polymerase II 
C-terminal domain repeats was reduced within 30 minutes of addi-
tion of 2x GI50 BMS-387032, but 4 to 7 hours were required for 
suppression of Ser2 phosphorylation (Fig. 5A). Rb Ser249/Thr252 
and Histone H3 Ser10 phosphorylation was only lost 7 to 16 hours 
after addition of drug, similar to the kinetics for loss of phosphory-
lation of CDK2 on Thr160, the critical activation loop threonine 
residue (Fig. 5A). While CDK9 is suspected to phosphorylate RNA 
polymerase II on Ser2,28 CDK7 is thought to be the critical kinase 
responsible for phosphorylation of both RNA polymerase II on Ser5 
and CDK2 on Thr160.32,33 These data suggest that at the minimum 
effective dose, BMS-387032 may only suppress CDK7 activity. The 
delayed loss of biomarkers of CDK9 and CDK2 activity may be due 
to the time required for phosphorylation of the activating loop thre-
onines of these kinases to be turned over.
An efficient inhibitor of CDK7 would be expected to evoke all the 
effects of a CDK2 inhibitor (albeit after a delay), but should also elicit 
additional responses via its effect on transcription. Short exposure to 
BMS-387032 is not, however, more lethal to U2-OS cells than corre-
sponding treatments with a CDK2 inhibitor; as for VER-54505, 24 
hours treatment was required to suppress proliferative potential (Fig. 
5B) and, at 4x GI50, was sufficient to trigger apoptosis after a delay 
(Fig. 5C). Nevertheless, we were keen to find out if BMS-387032, 
ablated proliferative potential by different means to a primarily 
CDK2-selective inhibitor, such as VER-54505.
U2-OS cells were treated for 24 hours with 0.5x to 4x GI50 of 
BMS-387032 and then lysed either immediately, or after 6 or 24 
hours recovery without drug. Similar to VER-54505, low doses 
(0.5–1x GI50) of BMS-387032 suppressed Rb Ser249/Thr252 and 
histone H3 phosphorylation in a partially reversible manner, but 
BMS-387032 treatment had additional consequences not observed 
with low doses of VER-54505 (compare Figs. 5D with 1C). Some of 
these effects were reversed upon drug removal, such as suppression 
that it occurs via caspase-dependent apoptosis. zVAD-fmk did not, 
however, rescue cells from either the block on proliferation or loss of 
clonogenicity imposed by VER-54505 (Fig. 2C and D). Apoptosis 
is therefore dispensable for the anti-proliferative effects of transient 
treatment with VER-54505.
Is suppression of Chk1 required for DNA damage, apoptosis 
or cell cycle arrest? VER-54505 reduces Chk1 levels (Fig. 1C), 
confirming the results of Maude and Enders18 obtained with the 
less selective CDK inhibitors, roscovitine and oloumucine. Chk1 
has an important role in stabilizing stalled forks under conditions 
of replication stress, which CDK inhibition imposes due to reduced 
origin firing.17,18 This begs the question: how important is the 
ability of CDK inhibitors to suppress Chk1 for their potential to 
induce DNA damage, apoptosis, permanent cell cycle arrest and loss 
of clonogenicity? Transient transfection of pCMV-Chk1 increased 
Chk1 levels and prevented their suppression by VER-54505, but 
did not stop the CDK inhibitor evoking caspase activation (Fig. 
3A), or suppressing the colony forming potential of U2-OS cells 
(Fig. 3B). Chk1 overexpression somewhat dampened the induction 
of H2AX phosphorylation by VER-54505, as did addition of the 
caspase inhibitor zVAD-fmk. Remarkably however, the combination 
of Chk1 overexpression and caspase inhibition completely prevented 
H2AX phosphorylation in response to VER-54505 addition (Fig. 
3A). Combined Chk1 overexpression and caspase inhibition did not 
allow Rb and Histone H3 phosphorylation to recover upon drug 
removal, and also failed to rescue long term proliferative potential 
(Fig. 3B). The ability of VER-54505 to downregulate Chk1 therefore 
influences its ability to evoke DNA damage, but is dispensable for its 
ability to trigger apoptosis and impose a long-term cell cycle arrest.
VER-54505 induced apoptosis is not a consequence of depletion 
of Mcl-1 and XIAP. Several recent reports attribute the cytotoxicity 
of CDK inhibitors to suppression of Mcl-1 and XIAP expression;14-16 
this is proposed to unleash pro-apoptotic factors already present in 
transformed cells as a consequence of oncogenic signaling. There 
was a close correlation between the doses of VER-54505 required 
to suppress Mcl-1 and XIAP, with those that induced caspase and 
PARP cleavage. To establish if the apoptosis evoked by VER-54505 
could be attributed to loss of Mcl-1 and/or XIAP, we suppressed their 
expression via RNA interference either singly, or together.
Immunoblots of U2-OS lysates prepared 48 to 72 hours post 
transfection indicated that siRNAs vs. Mcl-1 and XIAP dramatically 
reduced expression of the targeted gene; importantly, expression of 
both proteins could be stifled simultaneously (Fig. 4A). Knocking 
down Mcl-1 or XIAP resulted in little increase in the fraction of cells 
with a sub-G1 DNA content, although simultaneous depletion of 
both proteins increased the putative apoptotic fraction (at 72 hours 
post-transfection) from ~4% to ~8%. siRNA mediated depletion of 
Mcl-1, XIAP, or both proteins together, had little effect on the long-
term proliferative potential of U2-OS cells and also failed to increase 
the toxicity of 24-hour treatments with VER-54505 (Fig. 4B). The 
Figure 1. 24 hours exposure to CDK inhibitors is required for loss of proliferative potential. (A) The dose of VER-54505 required to block colony formation 
decreases with increased length of exposure. (B) Induction of apoptosis by VER-54505 is delayed. Bar graph showing the proportion of U2-OS cells in apop-
tosis (sub-G1) or various phases of the cell cycle after treatment with VER-54505 (2x GI50) for the indicated time. Where two times are shown, the first is time 
with drug and the second indicates the length of a subsequent incubation without drug. Cleavage of PARP to its lower molecular weight apoptosis-associated 
form was detected in samples with >20% sub-G1 DNA content (data not shown). (C) Immunoblot indicating the reversible and irreversible pharmacodynamic 
responses evoked by 24 hours treatment with VER-54505. U2-OS cells were treated with 0.5–4x GI50 VER-54505 for 24 hours; extracts were prepared 
either immediately or after 6 or 24 hours recovery without drug. See Materials and Methods for notes on the pharmacodymanic markers used. Consistent 
results were observed all three times this experiment was performed.
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Figure 2. Caspase inhibition rescues U2-OS cells from the acute 
toxicity of VER-54505 but not from loss of long term proliferative 
potential. (A) zVAD-fmk impairs VER-54505 induced cleavage 
of caspase 3 and 7 to their active forms. Cells were exposed 
to VER-54505 for 24 hours followed by 6 hours recovery with-
out drug in the presence or absence of zVAD-fmk (20 μM). (B) 
zVAD-fmk prevents VER-54505 inducing the appearance of cells 
with the sub-G1 DNA content characteristic of apoptosis. Cells 
were exposed to VER-54505 for 24 hours, then incubated for 
24 hours without CDK inhibitor; where zVAD-fmk was included, 
it was present for the entire 48 hour incubation. (C) zVAD-fmk 
addition rescues U2-OS cells from the cytotoxic effects of VER-
54505 (4x GI50) without impairing the ability of the CDK inhibi-
tors to inhibit growth/proliferation. (D) zVAD-fmk addition does 
not rescue U2-OS cells from the loss of clonogenicity evoked by 
24 hours treatment with VER-54505. Where caspase inhibitors 
were present they were added before VER-54505 and also re-
added after the CDK inhibitor was removed.
of RNA polymerase II Ser2 phosphorylation and XIAP 
expression, and increases in p53 levels and Histone H2AX 
phosphorylation on Ser139. Certain other effects, such 
as induction of a limited degree of caspase 7 and PARP 
cleavage, were not reversed when drug was removed. The 
effects of higher doses (2–4x GI50) BMS-387032 were 
almost identical to corresponding doses of VER-54505. 
Suppression of RNA polymerase II Ser2 phosphorylation 
and XIAP expression remained reversible, loss of Mcl-1 
expression becomes apparent, and no partial recovery of 
Rb and Histone H3 phosphorylation was observed upon 
drug removal.
The similarity in biomarker responses evoked by 
clonogenicity-eliminating doses of BMS-387032 and 
VER-54505 suggested that the ability of BMS-387032 
to induce apoptosis and DNA damage might also be 
dispensable for its effects on long term proliferative 
potential. As for VER-54505, addition of zVAD-fmk 
substantially rescues cells from BMS-387032 induced 
lethality, but not from a block on proliferation (data 
not shown), or clonogenicity (Fig. 5E). Similarly, Chk1 
overexpression (alone or in combination with zVAD addi-
tion) also failed to rescue the suppression of clonogenicity 
evoked by BMS-387032, even in a narrow quantitative 
sense (Fig. 5E).
Discussion
CDK inhibitors have multiple effects on cancer cells: 
blocking cell cycle progression, inducing DNA damage 
and provoking apoptosis. We set out to establish which 
of these effects were required to eliminate the long term 
proliferative potential of U2-OS cells. Our particular 
interest was in the consequences of CDK2 inhibition, 
but we found many “CDK2” inhibitors described in 
the literature were heavily compromised by off-target 
effects. Of the compounds tested, VER-54505 proved 
the most effective modulator of CDK2 activity in cells 
and consequently was used in our studies. At doses that 
suppress phosphorylation of CDK2 substrates, 7 hour 
treatments with VER-54505 were tolerated, but 24 hour 
treatments eliminated the colony forming abilities of 
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imposition of a sustained cell cycle arrest. Suppressing apoptosis with 
the cell-permeable caspase inhibitor, zVAD-fmk, had no effect on the 
ability of transient-treatment with VER-54505 to impair long-term 
proliferation of U2-OS cells, though cells were rescued from much 
of the cytotoxicity it normally caused. Therefore, at least in U2-OS 
cells, the apoptosis evoked by CDK inhibition merely accelerates the 
demise of cells whose ability to leave a colony of descendents has 
already been eliminated.
The DNA damage provoked by CDK inhibitors is believed to 
result from the suppression of Chk1 expression, which while not 
toxic in itself, becomes so under conditions of replication stress.18 
U2-OS cells. VER-54505 initially increased the fraction of cells in 
G2, but later provoked apoptosis, even if drug had been removed at 
24 h. Doses of VER-54505 that eliminated long term proliferative 
potential blocked CDK2 and CDK9 activity, stifled expression of the 
anti-apoptotic proteins Mcl-1 and XIAP, but also suppressed Chk1 
expression and induced the H2AX Ser139 phosphorylation associ-
ated with DNA damage.
Substantial suppression of long term proliferation was also 
imposed by lower doses of VER-54505 that failed to evoke apoptosis 
or DNA damage, raising the possibility that transient treatment with 
CDK inhibitors might be able to eliminate clonogenicity simply by 
Figure 3. (A) Immunoblot indicating that Chk1 overexpression blunts induction of H2AX phosphorylation by VER-54505. 24 hours post-transfection with 
either pCDNA3.1 or pCDNA-Chk1, VER-54505 was applied for 24 hours. Lysates were prepared from cells 6 hours after removal of VER-54505. Where 
zVAD-fmk (20 μM) was added it was present for the 24 hour incubation with VER-54505 and for the 6 hour recovery period. (B) The combination of Chk1 
overexpression and caspase blockade fails to rescue U2-OS cells from the block on colony formation imposed by transient treatment with VER-54505. 
pCDNA3.1 or pCDNA-Chk1 transfected cells were treated for 24 hours with 0–8x GI50 VER-54505, re-plated after trypsinization and allowed to proliferate 
for 10 days. Where caspase inhibitors were present they were added before the 24 hour incubation with VER-54505 and also re-added to the re-plated 
cells. Values on the graph represent the mean (+standard deviation) number ofcolonies observed in 4 repeats.
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them locked in a low CDK/cyclin activity state reminiscent of G0. 
The loss of Cdc25A may also interfere with activation of CDK4/
cyclin D complexes,40 reducing their ability to restore Rb phosphory-
lation by more than would be expected by the modest effect 2x GI50 
VER-54505 has on cyclin D1 levels.
Though apoptosis might not be required for the loss of clonoge-
nicity, the induction of programmed cell death is obviously sufficient 
to prevent further proliferation. A somewhat surprising finding of 
this work is that, at least in U2-OS cells, CDK inhibition does not 
trigger apoptosis via Mcl-1 and XIAP depletion. When we curbed 
expression of these anti-apoptotic factors from U2-OS cells by RNA 
interference, we did not observe dramatic apoptosis or a reduction 
in clonogenicity. Though this result is discordant with certain recent 
reports,14-16 it is not inconsistent with them as Mcl-1 and XIAP are 
merely the unstable members of two wider families of anti-apoptotic 
proteins.41 Logically, one would expect CDK inhibitors to only kill 
cells via depletion of Mcl-1 or XIAP, if they made a major quantita-
tive contribution to the complement of anti-apoptotic proteins in the 
cell line under test.
We have not established why transient treatment with 
CDK-inhibitors induces apoptosis in U2-OS cells, but it is inter-
esting to note that VER-54505 only induces apoptosis at doses 
that reduce phosphorylation of RNA polymerase II on Ser2, likely 
indicating suppression of CDK9.28 Strengthening this correlation, 
BMS-387032 evokes both downregulation of RNA polymerase II 
Ser2 phosphorylation and some degree of caspase activation at all 
doses tested. The apoptosis provoked by CDK inhibitors in U2-OS 
cells may therefore be due to inhibition of transcriptional CDKs 
rather than CDK2.
Despite the ability of BMS-387032 to evoke some apoptosis at 
low doses, it only ablated colony forming potential at doses where 
Rb and Histone H3 phosphorylation did not recover upon drug 
removal. As for VER-54505, overexpression of Chk1 and blockade 
of caspase activity made no difference to the dose of BMS-387032 
required to reduce or eliminate colony formation. In addition, 
Mcl-1 and or XIAP depletion did not modulate the toxicity of 
BMS-387032 (unpublished results). This indicates that the greater 
Following H2AX Ser139 phosphorylation as a marker, we found 
that overexpression of Chk1 reduced the amount of DNA damage 
caused by VER-54505, but did not prevent the compound trig-
gering caspase activation. We suspect that the residual DNA damage 
evoked by VER-54505 in Chk1-overexpressing cells may be a 
consequence of double-strand breaks caused by nucleosome cleavage 
in apoptosis,34 as combining Chk1 overexpression with addition 
of a caspase inhibitor prevented VER-54505 provoking any H2AX 
phosphorylation. Combined blockade of the ability of VER-54505 
to induce apoptosis and DNA damage did not, however, stop treat-
ment with the compound eliminating the colony forming potential 
of U2-OS cells.
VER-54505 suppresses CDK2 activity within 10 minutes of 
addition (see Fig. S2B). So why might inhibition of cell cycle CDK/
cyclin be tolerated for 7 hours, but evoke a long-term cell cycle arrest 
if the inhibition is sustained for 24 hours? As Chk1 overexpression 
prevents VER-54505 inducing DNA damage but fails to enable 
recovery of cell cycle progression, we do not think that the cell cycle 
arrest requires CDK inhibitor-mediated collapse of replication forks. 
We also suspect that the p53 response observed, which is probably 
evoked by inhibition of transcriptional CDK activity preventing 
Hdm2 synthesis,35 is also dispensable for the arrest; significant 
clonogenicity is lost at doses of VER-54505 that fail to induce 
p53, and the levels of p53 and p21 have dropped back to normal 
24 hours after removal of drug. Instead, we propose that the ability 
of CDK inhibitors to impose a sustained cell cycle arrest after 24 
hours, but not 7 hours, treatment rests on their ability to interrupt 
the synthesis of cyclins and CDK-activating phosphatases. When 
VER-54505 is present, Rb is dephosphorylated and is free to bind to 
and inactivate E2F1, resulting reduced synthesis of proteins encoded 
by E2F1-responsive genes such as Chk1 Cdc25A, cyclin E1 and 
cyclin B1,36-39 which in time translates into a dramatic reduction in 
the levels of these proteins (as observed in Fig. 1C). Once the levels 
of cyclin E1 and Cdc25A drop below a certain threshold (crossed 
sometime between 7 and 24 hours of drug exposure) cells lose the 
ability to re-phosphorylate and inactivate Rb and so are unable to 
restore E2F1-mediated transcription when drug is removed, leaving 
Figure 4. (A) XIAP and Mcl-1 levels can be dramatically reduced by RNA interference. Extracts were prepared from cells 48 hours post-siRNA transfection. 
siBoth indicates that cells were transfected with siRNAs vs.both Mcl-1 and XIAP; siNon indicates cells transfected with a control siRNA. The numbers below 
the GAPDH panel of the immunoblot indicate the fraction of cells with sub-G1 DNA content in parallel treated samples harvested at the same time. (B) siRNA 
vs. Mcl-1, XIAP or both mRNAs has little effect on the ability of U2-OS cells to form colonies and does not potentiate the effect of VER-54505. Note that for 
all conditions, colony numbers are expressed as a % age of those numbers for siNon-transfected cells that were not treated with CDK inhibitor.
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Figure 5. (A) Immunoblot demonstrating the kinetics with which phosphorylation of various biomarkers is lost when U2-OS cells are treated with 2x GI50 
BMS-387032. (B) The dose of BMS-387032 required to block colony formation decreases with increased length of exposure. (C) Induction of apoptosis 
by BMS-387032 is delayed. Bar graph showing the proportion of U2-OS cells in apoptosis (sub-G1) or various phases of the cell cycle after treatment with 
BMS-387032 (4x GI50) for the indicated time. Where two times are shown, the first is time with drug and the second indicates the length of a subsequent 
incubation without drug. Cleavage of PARP to its lower molecular weight apoptosis-associated form was detected in samples with >20% sub-G1 DNA content 
(data not shown). (D) Immunoblot indicating the reversible and irreversible pharmacodynamic responses evoked by 24 hours treatment with BMS-387032. 
Cells were treated with 0.5–4x GI50 BMS-387032 for 24 hours; extracts were prepared either immediately or after 6 or 24 hours recovery without drug. 
See Materials and Methods for notes on the pharmacodymanic markers used. (E) The combination of Chk1 overexpression and caspase blockade fails to 
rescue U2-OS cells from the block on colony formation imposed by transient treatment with BMS-387032. pCDNA3.1 or pCDNA-Chk1 transfected cells 
were treated for 24 hours with 0–8x GI50 BMS-387032, re-plated after trypsinization and allowed to proliferate for 10 days. Where caspase inhibitors 
were present they were added before the 24 hour incubation with BMS-387032 and also re-added to the re-plated cells. Values on the graph represent the 
mean (+standard deviation) number of colonies observed in 4 repeats.
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minutes with TBS-T. Horseradish peroxidase (HRP)-conjugated 
secondary antibodies were detected using ECL or ECL+ kits (GE 
Healthcare Lifesciences, Little Chalfont, UK), as appropriate. Many 
biomarkers were employed in this project and citations for their use 
are given below: RNA polymerase II Ser 5 is a target for phospho-
rylation by CDK9;28 Rb is phosphorylated on Ser249/Thr252 by 
CDK2;24-26 Histone H3 Ser10 is phosphorylated by Aurora B, but 
only in mitosis when CDK1 is active;27 H2AXSer139 is a marker of 
DNA damage;29 cleavage of caspase 7 and PARP is characteristic of 
apoptosis; results for XIAP, Mcl-1, p53, Chk1 and cyclin B1 indicate 
changes in abundance, rather than phosphorylation or cleavage. 
Sources of antibodies were: Abcam (Cambridge, UK) for anti-RNA 
pol II CTD Ser2 (ab 5095) and anti-cyclin E (HE12) (ab3927); 
Biosource (Nivelles, Belgium) for anti phospho-Rb Ser249/Thr252 
(44-584G); Cell Signaling Technology (via NEB UK, Hitchin, 
Herts, UK) for anti-cyclin B1 (#4135), ant-cyclin D1 (#2922), 
anti-Chk1 (#2345), anti-cleaved caspase 7 (#9491), anti-nucleo-
phosmin Thr199 (#3451), anti-p53 (#9282), anti-PARP (#9542) 
and anti-XIAP (#2042); Upstate (Dundee, UK) for anti-phospho 
histone H2AX Ser139 (07-164) and anti-phospho histone H3 Ser10 
(06-570); and Santa Cruz (Heidelburg, Germany) for anti-Cdc25A 
(sc97), anti-Mcl-1 (sc20679), anti-p21 (sc397) and anti-RNA pol II 
CTD Ser5 (sc13583). HRP-conjugated secondary antibodies were 
from by GE Healthcare Lifesciences. Rb Ser249/Thr252 phosphory-
lation was also assayed using an ELISA kit from Biosource (Nivelles, 
Belgium) according to the manufacturers instructions. DNA replica-
tion was measured using the Cell Proliferation ELISA kit from Roche 
Applied Science.
Flow cytometry. After drug treatment for the indicated times, the 
entire population of cells was fixed in ice-cold 30% PBS/70% EtOH 
on ice for 1–2 hours. Cells were resuspended in PBS + propidium 
iodide (50 μg/ml) and DNAse free-RNAse A (50 μg/ml) and incu-
bated at 37°C for 60 minutes. The DNA content of each cell was 
measured using a Beckon Dickinson FACScan instrument. Sub G1, 
G1, S-phase and G2/M populations were identified by reference to 
untreated populations of the same cell line.
Clonogenic assays. Cells were detached by trypsin-EDTA, then 
plated at ~500 cells per well in 6-well plates. After 18 hours recovery, 
drugs were applied at 0, 0.5x, 1x, 2x, 4x and 8x GI50 multiples for 
various times. Drug containing media was removed, cells washed 
with PBS, then incubated for 5–8 days in drug-free media. Colonies 
(containing >30 cells) were counted after staining/fixation with 
0.25% crystal violet in 10% paraformaldehyde. Results indicate 
the %age of colonies formed relative to untreated controls. For 
assays performed on siRNA- or plasmid-transfected cells, cells were 
detached and replated 48 hours post-transfection and then (after 6 
hours recovery) treated for 18 hours with drug. pCDNA-Chk1 was 
purchased from Origene and used alongside pCDNA3.1 as a control. 
siRNAs vs. Mcl-1 (Hs_MCL1_6) and XIAP (Hs_BIRC4_5) were 
from Qiagen, as was the Allstars negative control siRNA, siNon.
Kinase assays. CDK1/cyclin B, CDK2/cyclin A, CDK7/cyclin 
H and CDK9/cyclin T1 assays were performed as described in ref. 
50; Chk1, GSK3β and PDK1 were assayed as described in ref. 23. 
IC50 values were estimated from assays where inhibitor was varied 
over a 512-fold range (as a 10-point doubling dilution series). 
Results quoted are the average of ≥2 independent experiments. ATP 
concentrations were at the KM for the particular kinase in question. 
pro-apoptotic properties of BMS-387032 do not increase its ability 
to suppress long-term proliferative potential above that which can 
be accounted for by its ability to impose a sustained cell cycle arrest. 
CDK2 may therefore be the critical target of inhibitors that primarily 
target transcriptional CDKs, even if they only modulate the cell cycle 
kinase indirectly via effects on CDK7.
What are the consequences of these findings regarding the mode of 
action of CDK inhibitors for cancer therapy? We have demonstrated 
that in one cancer cell line, the sustained inhibition of CDK2 may 
be sufficient to eliminate proliferative potential. It is not currently 
clear, whether these results would also be typical of untransformed 
dividing cells. However, even if most untransformed cells in cycle 
can withstand 24-hours inhibition of CDK2, it only takes the cells 
of one vital tissue system to be sensitive for the therapeutic window 
to be closed. We would also note that while suppression of Mcl-1 or 
XIAP may not account for CDK inhibitor cytotoxicity in U2-OS 
cells, it is clearly critical in other systems.14-16 Perhaps the key to the 
successful use of CDK inhibitors in the therapy of malignancy will be 
to identify those inhibitors that downregulate CDK9 at lower doses 
than they suppress CDK2 or CDK7 activity (the latter will lead to 
the first). Such inhibitors should then be used in indications where 
Mcl-1 suppression evokes apoptosis, such as chronic lymphocytic 
leukemia.42,43 Alternatively, less specific CDK inhibitors may prove 
useful where they can be applied as a short bolus against Mcl-1 or 
XIAP-dependent malignancies that succumb to short interruptions 
of synthesis of these antiapoptotic proteins. Such modalities might 
kill sensitive tumor cells but leave the proliferative potential of transit 
amplifying populations in vital organs unaffected.
Materials and Methods
Cell lines and culture conditions. U2-OS (LGC-Promochem) 
were cultured in DMEM supplemented with fetal calf serum (10%) 
and penicillin/streptomycin (1%). Transfections were performed with 
Lipofectamine 2000 in Optimem according to the manufacturers 
instructions (for all the above: Invitrogen, Paisley, UK). For prolif-
eration assays, cells were plated at 1000–3000 cells/well in 96 well 
plates and drug applied for 72 hours. TCA fixed cells were stained 
with sulforhodamine B (SRB) and GI50 concentrations calculated 
from inflexion points of dose-response curves using Excel-fit software 
(IDBS Limited). The Biomass estimates in Figure 2B represent mean 
SRB staining of 8 wells either fixed prior to drug addition (defined as 
100%), 24 hours after drug addition, or after 24 or 48 hours recovery 
from a 24 hour treatment with VER-54505. Where zVAD-fmk was 
included it was present for the entire experiment.
Compounds. BMS-387032 and VER-54505 were synthesized as 
described in refs 9 and 44, respectively. Roscovitine;45 5,6-dichloro-1-
β-D-ribofuranosylbenzimidazole (DRB);46 RGB-286147 (CDK/Crk 
inhibitor);47 compound 32 (CDK2/9 inhibitor);48 and SU-9516,49 
were all obtained from Calbiochem.
Immunoblotting and ELISA analysis. For immunoblotting, cell 
lysates (containing 15 μg protein) were separated by SDS-PAGE 
and transferred to PVDF membranes, which were then blocked for 
1 hour with TBS-T (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 0.1% 
Tween 20) plus 5% non-fat dry milk. After incubation with primary 
antibody (in blocking solution) for 2 to 18 hours, membranes were 
washed for 3 x 5 minutes with TBS-T, probed with secondary 
antibody (in blocking solution) for one hour, then washed 3 x 5 
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